|Page (1) of 1 - 08/09/17||email article||print page|
(August 09, 2017)
DUBLIN--(BUSINESS WIRE)--The "Dry Powder Inhaler Devices Market - Forecast (2016-2022)" report has been added to Research and Markets' offering.
Dry-powder inhaler (DPI) is an alternative device to the aerosol-based inhalers commonly called metered-dose inhaler (or MDI) and help in delivering medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD, although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus.
Globally, increasing number of people with respiratory diseases and diabetes mellitus are expected to remain the growth drivers for dry powder inhaler devices during the period of study. Geographically, North America dominated the dry powder inhaler devices market driven by a world class healthcare infrastructure with a technologically advanced practice, higher spending, a high number of people with respiratory problems, strict guidelines and presence of key industry players in the region.
North America was followed by Europe and Asia-Pacific as second and third largest market for dry powder inhaler devices market. Asia Pacific is projected to have the fastest growth, owing to a rapidly developing medical infrastructure, increasing spending on healthcare and growing medical tourism in developing nations such as China and India in this region.
- Bayer HealthCare AG Company
- GlaxoSmithKline Plc
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- AKELA Pharma Inc.
- Pharmaxis Limited
- Hovione FarmaCiencia SA
- Nanotherapeutics, Inc
- OPKO Health, Inc.
Key Topics Covered:
1. Market Overview
2. Executive Summary
3. Market Landscape
4. Market Forces
5. Strategic Analysis
6. Dry powder inhaler devices Market, By Type
7. Dry powder inhaler devices Market, By Therapeutics
8. Dry powder inhaler devices Market, By Geography
9. Dry powder inhaler devices Market - Entropy
10. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/5x7n93/dry_powder
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs, Inhalers and Nebulisers, Respiratory Devices